Drug firm Strides Acrolab today said that it has received American health regulator Food and Drug Administration's (FDA) nod for marketing and distributing Bacitracin injections, an anti-infective used to treat pneumonia, in the US.
The company, in a filing to the Bombay Stock Exchange, said that the FDA's nod for Bacitracin injections is the seventh sterile injectables approval received by the company in the current year.
According to the market research firm IMS, the total US market for the drug is around $32 million. Strides expects the launch to happen by the third quarter of 2010.
The company will introduce the drug in the US market through Sagent Pharmaceuticals, with which Strides had signed a pact for developing and supplying more than 25 injectables.
Under the 2007 pact, Strides was required to develop and supply 25 injectables, which would then be marketed in the US by Sagent.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app